537 related articles for article (PubMed ID: 26471511)
21. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.
Baum MM; Butkyavichene I; Churchman SA; Lopez G; Miller CS; Smith TJ; Moss JA
Int J Pharm; 2015 Nov; 495(1):579-587. PubMed ID: 26386138
[TBL] [Abstract][Full Text] [Related]
22. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE;
BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918
[TBL] [Abstract][Full Text] [Related]
23. Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis.
Hojilla JC; Vlahov D; Glidden DV; Amico KR; Mehrotra M; Hance R; Grant RM; Carrico AW
J Int AIDS Soc; 2018 Mar; 21(3):e25103. PubMed ID: 29577616
[TBL] [Abstract][Full Text] [Related]
24. Associations between perceived barriers and benefits of using HIV pre-exposure prophylaxis and medication adherence among men who have sex with men in Western China.
Hu Y; Zhong XN; Peng B; Zhang Y; Liang H; Dai JH; Zhang JY; Huang AL
BMC Infect Dis; 2018 Nov; 18(1):575. PubMed ID: 30442106
[TBL] [Abstract][Full Text] [Related]
25. Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database.
Rossotti R; Borghi V; Callegaro AP; Micheli V; Bruzzone B; Colao G; Gismondo MR; Vicenti I; Penco G; Zazzi M; Rusconi S
J Clin Virol; 2016 Oct; 83():48-53. PubMed ID: 27591555
[TBL] [Abstract][Full Text] [Related]
26. HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise.
Hendrix CW
Clin Pharmacol Ther; 2018 Dec; 104(6):1082-1097. PubMed ID: 30199098
[TBL] [Abstract][Full Text] [Related]
27. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.
Trang TP; Dong BJ; Kojima N; Klausner JD
Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203
[TBL] [Abstract][Full Text] [Related]
28. Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence.
Hanscom B; Janes HE; Guarino PD; Huang Y; Brown ER; Chen YQ; Hammer SM; Gilbert PB; Donnell DJ
J Acquir Immune Defic Syndr; 2016 Dec; 73(5):606-608. PubMed ID: 27846073
[TBL] [Abstract][Full Text] [Related]
29. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN
Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774
[TBL] [Abstract][Full Text] [Related]
30. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
Özdener AE; Park TE; Kalabalik J; Gupta R
Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
[TBL] [Abstract][Full Text] [Related]
31. Low willingness and actual uptake of pre-exposure prophylaxis for HIV-1 prevention among men who have sex with men in Shanghai, China.
Ding Y; Yan H; Ning Z; Cai X; Yang Y; Pan R; Zhou Y; Zheng H; Gao M; Rou K; Wu Z; He N
Biosci Trends; 2016 May; 10(2):113-9. PubMed ID: 27052151
[TBL] [Abstract][Full Text] [Related]
32. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
Weis JF; Baeten JM; McCoy CO; Warth C; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Mugo N; Matsen FA; Celum C; Lehman DA;
AIDS; 2016 Jan; 30(1):31-5. PubMed ID: 26731753
[TBL] [Abstract][Full Text] [Related]
33. Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons.
Pattacini L; Murnane PM; Baeten JM; Fluharty TR; Thomas KK; Bukusi E; Katabira E; Mugo N; Donnell D; Lingappa JR; Celum C; Marzinke M; McElrath MJ; Lund JM;
J Infect Dis; 2015 Jun; 211(12):1943-52. PubMed ID: 25520426
[TBL] [Abstract][Full Text] [Related]
34. Motives of Dutch men who have sex with men for daily and intermittent HIV pre-exposure prophylaxis usage and preferences for implementation: A qualitative study.
Bil JP; van der Veldt WM; Prins M; Stolte IG; Davidovich U
Medicine (Baltimore); 2016 Sep; 95(39):e4910. PubMed ID: 27684827
[TBL] [Abstract][Full Text] [Related]
35. In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs?
Mitchell KM; Dimitrov D; Hughes JP; Xia F; Donnell D; Amico KR; Bokoch K; Chitwarakorn A; Bekker LG; Holtz TH; Mannheimer S; Grant RM; Boily MC
AIDS; 2018 Mar; 32(6):809-818. PubMed ID: 29424774
[TBL] [Abstract][Full Text] [Related]
36. Pre-exposure prophylaxis (PrEP) for men who have sex with men in Europe: review of evidence for a much needed prevention tool.
Reyniers T; Hoornenborg E; Vuylsteke B; Wouters K; Laga M
Sex Transm Infect; 2017 Aug; 93(5):363-367. PubMed ID: 27872326
[TBL] [Abstract][Full Text] [Related]
37. The European preexposure prophylaxis revolution.
Cairns G; McCormack S; Molina JM
Curr Opin HIV AIDS; 2016 Jan; 11(1):74-9. PubMed ID: 26599164
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.
Nichols BE; Boucher CAB; van der Valk M; Rijnders BJA; van de Vijver DAMC
Lancet Infect Dis; 2016 Dec; 16(12):1423-1429. PubMed ID: 27665989
[TBL] [Abstract][Full Text] [Related]
39. Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation.
Landovitz RJ
Top Antivir Med; 2015; 23(2):85-90. PubMed ID: 26200708
[TBL] [Abstract][Full Text] [Related]
40. PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention.
Mayer KH; Allan-Blitz LT
J Acquir Immune Defic Syndr; 2019 Dec; 82 Suppl 2(2):S113-S117. PubMed ID: 31658197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
